

February 3, 1970

Dr. S. K. Vanov, M.D.
The Upjohn Co.
Kalamazoo, Michigan

Dear Dr. Vanov,

Thank you for your inquiry and invitation to participate in the evaluation programs of new psychotropic drugs, particularly anti-anxiety compounds.

As Dr. Simeon may have described, our principal interest is in the identification and classification of novel psychoactive agents by neurophysiologic, particularly EEG, measures. Our clinical studies are derivative, and we have undertaken clinical studies to support our EEG determinations. We have identified the psychoactive properties of cyclazocine, doxepin and fenfluramine by EEG profile analyses, and now are engaged in the analyses of four 'numbered' compounds. For one of these, G41299, we have begun the clinical trials.

To undertake these studies we require some evidence of the safety of the compound in man, preferably normal adult volunteers, and a synopsis of the dosage/animal data. May I suggest that if such an analysis is of interest, that you arrange to visit our laboratories at your convenience, and review the type of programs which are now in progress? It may be particularly helpful if you sent us a copy of the information which we request, so that we could discuss a specific protocol during your visit-- but, this is not necessary, and may be deferred.

Thank you again for your interest.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

mf/